Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
19. Mai 2021 17:00 ET
|
Adaptimmune Therapeutics plc
- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - ...